MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias
Status:
Recruiting
Trial end date:
2024-04-02
Target enrollment:
Participant gender:
Summary
This is a clinical trial to determine if Lamotrigine is non-inferior to Mexiletine for the
treatment of myotonia in patients with Non-Dystrophic Myotonia.
Non-dystrophic Myotonia is a genetic condition for which there is no cure. It affects
patients for the duration of their life and impacts work, leisure and can lead to significant
morbidity.
The study is a cross-over design - participants will be randomized to either lamotrigine or
mexiletine first for 8 weeks and then swap over after a week wash-out to the other medication
for a further 8 weeks. Participants and investigators will be blinded to the treatment
schedule. 60 participants will recruited through the clinical service, national registry and
national liaison.